As part of the 6-month SME Instrument project, TAmiRNA will partner with the Institute for Pharmaeconomic Research in Vienna (www.ipf-ac.at) to develop a health economic model, which will allow a precise estimation of the socio-economic benefit that can be obtained by introducing the OsteomiR test into the daily routine of osteoporosis risk assessment. In addition, TAmiRNA will identify partners for assay development and manufacturing to prepare for the launch of the research-use test kit and clinical utility studies.
About the purpose of the Horizon 2020 dedicated SME Instrument “PHC-12”:
This program addresses the challenge that only few novel biomarkers are validated for use in a clinical research setting. Such validation implies the demonstration of a link to a pertinent clinical endpoint or process, as well as a robust and appropriate analytical method. Therefore, the clinical validation of biomarkers will be increasingly important for the development of new diagnostics, and this is a research area where many small European companies are active.
TAmiRNA GmbH is a biopharmaceutical R&D company founded to drive the discovery and development of microRNAs (miRNAs) as tools for diagnosis and treatment of age-associated disorders such as Osteoporosis, Cardiovascular Disease and Neurodegenerative Disease. TAmiRNA targets to improve patient stability and quality of life with increasing age, by providing solutions for early risk assessment of disease and combined therapeutic treatment solutions.